QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saad, A. A Articles by Higa, G. M Search for Related Content PubMed PubMed Citation Articles by Saad, A. A Articles by Higa, G. M

ONCOLOGY

Treatment of Multiple Myeloma in the Targeted Therapy Era

Assistant Professor, Section of Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI

Manish Sharma, MD

Fellow, Section of Hematology/Oncology, Department of Medicine, School of Medicine, West Virginia University, Morgantown, WV

Gerald M Higa, PharmD

Associate Professor, School of Pharmacy, Mary Babb Randolph Cancer Center, West Virginia University

Reprints: Dr. Higa, School of Pharmacy, Robert C Byrd Health Sciences Center, PO Box 9520, West Virginia University, Morgantown, WV 26506, fax 304/293-7672, ghiga{at}hsc.wvu.edu

OBJECTIVE: To review the clinical trials that have impacted treatment standards of multiple myeloma (MM).

DATA SOURCE: A PubMed search (1980–June 2008) restricted to English-language publications was conducted using the key words multiple myeloma, clinical trials, targeted therapy, thalidomide, lenalidomide, bortezomib, dexamethasone, melphalan, autologous stem-cell transplantation, and tumor biology. Abstracts emanating from the meetings of the American Society of Clinical Oncology and American Society of Hematology from June 2002 to June 2008 were also reviewed.

DATA SYNTHESIS: Although hematopoietic stem-cell transplantation has improved the response rate and duration of overall survival, MM remains an incurable disease. However, focused research aimed at the molecular basis of the disease has led to a number of new treatment strategies. Evidence from clinical trials indicates that each of the 3 novel agents, thalidomide, lenalidomide, and bortezomib, is remarkably effective as first-line therapy. The data also suggest that clinicians may need to reevaluate the role of stem-cell transplantation in the disease.

CONCLUSIONS: Thalidomide, lenalidomide, or bortezomib in combination with dexamethasone have replaced traditional chemotherapy such as melphalan, doxorubicin, and vincristine as initial therapy of patients with MM who are eligible for stem-cell transplantation. Furthermore, these novel drugs can be incorporated into regimens used to treat transplant-ineligible patients or those with relapsing disease.

Key Words: autologous stem-cell transplantation, bortezomib, dexamethasone, lenalidomide, melphalan, multiple myeloma, thalidomide

Published Online, February 3, 2009. www.theannals.com, DOI 10.1345/aph.1L428

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-09-004-H01-P

This article has been cited by other articles:

				C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio, E. Negri, P. Boyle, and F. Levi Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975 Ann. Onc., November 30, 2009; (2009) mdp530v1. [Abstract] [Full Text] [PDF]